Kornimate/medical-research-clean huggingface dataset:
endometrial advancement after rec or u-hcg triggering

Conditions: Infertility

Summary: the purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhcg) with recombinant human chorionic gonadotropin (rechcg) for final oocyte maturation with regard to ovarian hyperstimulation syndrome (ohss)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

biopsies of endometrium were taken in different groups pregnancy rates were compared among defferent groups

Eligibility criteria:
inclusion criteria: * less than 36 years old * male or tubal infertility * fsh\<12 on day 3 exclusion criteria: * endometriosis stage 3 \& 4

Keywords: endometrium histology pregnancy
evaluating skin appearance following 5-flourouracil cream for treatment of actinic keratosis and the effects of topical agents

Conditions: Actinic Keratoses

Summary: this proposed project will be an open-label, split face, randomized controlled pilot study. up to 60 patients with diffuse facial actinic keratosis will be enrolled in the study. the purpose of this study is to understand the change in skin appearance throughout 5-fu treatment course and to examine whether a topical corticosteroid and moisturizer can decrease severity and duration of skin inflammation after 5-fu treatment course.

the purpose of this study to understand the change in skin appearance during and after the course of 5-fu cream in patients with ak, and compare how the appearance of skin inflammation changes with the use of topical corticosteroids and moisturizers.

Eligibility criteria:
inclusion criteria: * male and female, at least 18 years of age * subject must have a diagnosis of actinic keratosis (at least 5 lesions on each side of the face) * able to comprehend and read the english language exclusion criteria: * subjects who do not fit the inclusion criteria * concurrently have other inflammatory skin conditions. * prior known allergy to any components to of 5fu cream, topical steroid ointment or vaseline. • subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures (i.e.: compliant with using 5-fu cream, topical corticosteroid or moisturizers * those that are prisoners or cognitively impaired.
cross-cultural adaptation of the chinese version of qolaf-q (quality of life in patients with anal fistula questionnaire) ：a multi-center study

Conditions: Anal Fistula

Summary: the investigators verify the reliability and practicality of the chinese adaptation results of qolaf-q, which helps chinese doctors better master the methods and techniques of quality of life assessment.

when the investigators conduct cross-cultural adaptation to verify the applicability of qolaf-q in china, the investigators also compare it with the cross-cultural adaptation results of other language versions of this scale. while verifying the reliability and practicality of the chinese adaptation results of qolaf-q, the investigators also explore its differences, which helps chinese doctors better master the methods and techniques of quality of life assessment, pay more attention to the physical and mental health of patients, improve the quality of life and satisfaction of patients, and provide a reference for the development of more scientific, effective, and practical scales.

Eligibility criteria:
inclusion criteria: 1. meeting the diagnostic criteria for anal fistula in the "diagnostic criteria for anal fistula (2004 edition)", and being diagnosed through clinical examinations, digital rectal examinations, anorectal ultrasound, mri, and other examinations; 2. being 18 years old or above; 3. having clear consciousness and being able to understand and cooperate to complete the questionnaire survey; 4. voluntarily signing the informed consent form. exclusion criteria: 1. having other serious anorectal diseases, such as anal fissure, rectal prolapse, colorectal cancer, etc.; 2. having severe dysfunction of important organs such as the heart, liver, and kidneys; 3. suffering from mental diseases or having cognitive impairments; 4. having undergone anorectal surgery or other major surgeries that may affect the quality of life recently (within 3 months).
study of islet transplantation in type 1 diabetic kidney transplant recipients

Conditions: Diabetes Mellitus, Type I

Summary: the purpose of the study is to learn if islet transplantation is an effective treatment for type 1 diabetes in people who have had a kidney transplant. the primary objectives of the study are: - to set up islet transplantation in patients who have had a kidney transplant and who are using an immunosuppressive regimen that works the secondary objective of the study is: * to find out if successful islet transplantation leads to improved metabolic control and reduced renal complication from diabetes

patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence. for the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (atg, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft. induction therapy for subsequent transplants will be 2doses of basiliximab. all patients will receive etanercept to promote engraftment.

Eligibility criteria:
inclusion criteria: * male and female subjects * age 18 to 70 years of age * have insulin dependent diabetes mellitus type 1 * are post-renal transplant on maintenance immunosuppression with stable renal function * hba1c \> 7.5% or \< 7.5% and hypoglycemia unawareness exclusion criteria: * weight more than 90 kg * insulin requirement \> 60 units/day * other (non-kidney) organ transplants except prior failed pancreatic graft. * untreated or unstable proliferative diabetic retinopathy * presence of de novo antibody production since the renal allograft or either class i or class ii panel-reactive anti-hla antibodies * active infection * negative screen for epstein-barr virus (ebv) * any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin * history of factor v leiden mutation * any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g. warfarin) after transplantation (low-dose aspirin treatment is allowed) or subjects with international normalized ratio (inr) \> 1.5 * severe co-existing cardiac disease * persistent elevation of liver function tests at the time of study entry * acute or chronic pancreatitis * male subjects with elevation of prostate specific antigen * pregnancy * positive screen for polyoma (bk) virus * untreated hyperlipidemia * recent hemorrhagic stroke * factors associated with an increased risk of bleeding contact pi for complete incl-excl criteria list.

Keywords: type i diabetes islet after kidney transplant islet transplantation
clinical evaluation of integrative practices units infant and child care for unit children with typical or atypical autism (autism)

Conditions: Autism

Summary: the research project is part of the evaluation of the therapeutic approaches in mental health. its framework infant and juvenile units that have developed "integrative devices," taking into account recent advances in knowledge and providing care, education and pedagogical approach. the evolution of autistic children receiving these integrative devices is studied to determine the validity of the devices mentioned. the methodology is based on case studies in a natural situation. clinicians are committed to network among themselves and with researchers in a multicenter study.


Eligibility criteria:
inclusion criteria: * children 3 to 6 years with diagnosis f84.0 and f84.1 according to icd-10. the diagnosis should be made according to the criteria established by the recommendations on the diagnosis (ffp / has 2005). * children supported in care units that meet the criteria defined integrative practices. * children receiving a volume of hours of intervention between two and four half-days per week. * written parental consent collection. exclusion criteria: * presence of co-morbidities such epilepsia, serious organ damage, somatic and sensory.

Keywords: children aged 3 to 6 years
use of drugs and constipation in nursing homes

Conditions: Constipation; Diarrhea

Summary: the purpose of this study is to study factors (drugs, serum concentration of drugs, nutrition, physical activity, demographics, diseases etc.) related to constipation and diarrhea in nursing homes, and the effect of different laxative regimens.


Eligibility criteria:
inclusion criteria: * above 60 years old * stayed in nursing homes for more than 8 weeks * informed consent exclusion criteria: * expected discharge within 2 weeks * organic disorders causing constipation and diarrhea

Keywords: aged polypharmacy adverse effects nursing homes
comparative effectiveness of two different approaches to radiofrequency ablation of lumbar medial branch nerves

Conditions: Lumbar Spondylosis

Summary: the purpose of this voluntary research study is to determine whether the parasagittal approach to lumbar medial branch (lmb) nerve radio frequency ablation (rfa) will have greater efficacy than the traditional approach to lumbar medial branch nerve radio frequency ablation.

to determine whether the parasagittal approach to lumbar medial branch (lmb) nerve radiofrequency ablation (rfa) will have greater efficacy than the traditional approach to lumbar medial branch nerve radiofrequency ablation. this will be accomplished by comparing the results between the newly proposed parasagittal approach and the traditional approach of medial branch rfa done on the same patient (different sites) with bilateral low back pain (lbp). traditional approach: the electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (sap) and transverse process (tp) of the vertebral body to target the traversing medial branch nerve. the reason for the proposed angle is to avoid the mamillo-accessory ligament (mal) that may be ossified in up to 10% of the normal spine and, in such cases, potentially prevent proper coagulation of the medial branch nerve during the rfa procedure. parasagittal (new) approach: recently, tran et al. showed that mal is located more dorsally than it was thought earlier and, therefore, can't interfere with nerve coagulation during the rfa. consequently, they proposed abandoning the 20-degree angle used for the traditional approach and placing the radiofrequency cannula parasagittally and more dorsally. it is proposed that, in order to achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. the remainder of the procedure does not differ from the traditional method.

Eligibility criteria:
inclusion criteria: 1. bilateral equally intense axial low back pain 2. pain duration of ≥ 6 months 3. three-day average nrs scores of ≥ 3/10 4. age greater than 18 years 5. failure of conservative treatment, including nonsteroidal anti-inflammatory medications and physical therapy 6. positive response to a series of two bilateral diagnostic lumbar medial branch nerve blocks (≥ 80% pain relief). this is the current standard of care. exclusion criteria: 1. radicular pain below the knee 2. systemic infection or localized infection at the anticipated introducer entry site 3. pregnancy 4. allergy to lidocaine 5. bleeding dyscrasias 6. patients unable to give informed consent 7. history of lumbar spine surgery at the affected levels 8. history of previous bilateral lumbar rfa of medial branches within the past six months. 9. significant comorbid somatization or widespread pain with central sensitization 10. secondary gain identified due to ongoing legal proceedings or worker's compensation 11. cognitive impairment 12. any pre-existing condition at the discretion of the provider that may confound interpretation of results -
investigation of pain during subcutaneous injections with different injection speed and volume combinations

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems

Summary: this trial is conducted in europe. the aim of this trial is to assess and describe the pain in relation to subcutaneous (under the skin) injection of different combinations of injection speed and volume with respect to acceptance of the injection pain and backflow.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. * type 1 or type 2 diabetes * daily injection(s) with anti-diabetic drug (insulin or glucagon like peptide-1 (glp-1) analogues) via pen-injector or vial/syringe for more than 6 months * body mass index (bmi) between 18.5 and 30.0 kg/m\^2 (both included) * caucasians exclusion criteria: * known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit * previous participation in this trial. participation is defined as: screened * receipt of any investigational medicinal product that can influence pain perception within 14 days before screening * injection of more than 40 units of insulin per injection * continuous subcutaneous insulin infusion use within the last 6 months * continuous glucose monitoring use within the last 6 months * intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses) * known active or in-active skin disease in the injection area or that may affect pain perception * anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. however, not on the day of the injections)
treatment in patients with globus: psychoeducation, anxiolytics or proton pump inhibitors

Conditions: Globus

Summary: a randomized controlled trial study is conducted to compare treatment efficacy between psycho-education, anxiolytics drug and proton pump inhibitors in participants who met the criteria of globus.

this is a randomized controlled trial in patients with globus. all participants will be allocated into 3 groups (16 subjects/group) : proton pump inhibitors (miracid®) , anxiolytics drug (deanxit®) and psycho-education. the study duration is 4 weeks long. data regarding clinical severity and quality of life of all participants will be collected at the beginning and at the end of treatment.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * symptoms based on the following criteria: persistent or intermittent nonpainful sensation of a lump or foreign body in the throat with no structural lesion identified on physical examination, laryngoscopy, or endoscopy. 1. occurrence of the sensation between meals. 2. absence of dysphagia or odynophagia exclusion criteria: * subjects with psychological disease * significant heart disease and/or arrhythmia * proton pump inhibitors and/or histamine 2 receptor antagonist use within 2 weeks before randomization * mono-amine oxidase inhibitors or selective serotonin reuptake inhibitor or tricyclic antidepressant use within 2 weeks before randomization * history of drug allergy that use in research * pregnancy or breast feeding * decline to participate in study
optmizing advanced stage hodgkin lymphoma patients therapy

Conditions: Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category); Hodgkin Disease; Hodgkin Lymphoma

Summary: this is a prospective, multi-center, open-label, phase ii clinical trial, aims to assess the effectiveness of the combination acvd (adriamycin, cyclophosphamide, vinblastine and dacarbazine) and bv (brentuximab vedotin) in pet-2 positive advanced-stage hl patients, in order to improve the overall long-term disease control in the entire cohort of advanced-stage hl.

with the aim of reducing blemoycin pulmonary injury (bpi) , bleomycin was withdrawn and substituted with cyclophosphamide (acvd cycle) in patients with a pet-2 negative. all advanced stage hl patients will receive 2 cycles of the standard treatment abvd and assessed with pet-2 scan. knowing that cyclophosphamide toxicities include cytopenias, amenorrhea and male infertility. these toxicities are mainly dependent on the total cumulative dose. doses less than 4 g/m2 are not associated with sterility or major toxicity, doses higher than this can lead to azoospermia which was reversible in many cases therefore the cumulative dose will be used in this study is 3200 mg. additionally, brentuximab vedotin has shown significant activity in relapsed refractory hl with minor toxicities. pet scan after 2 cycles of abvd has proven to be an excellent tool to identify patients that will have long term pfs of 95% when it is negative and only progression-free survival (pfs) of less than 15% when it is positive. the primary endpoint of the study will be to assess the overall 3-y pfs of the entire cohort of patients.

Eligibility criteria:
inclusion criteria: * all the following parameters should be met * newly diagnosed untreated ,histologically proven cd30 positive classical hodgkin lymphoma (chl) * advanced stage (stage iib to ivb) as defined by ann arbor staging system (appendix 1) * age ≥ 14, \< 60 years * ecog performance status 0-2 * written informed consent for the trial * adequate contraceptive precautions for all patients of childbearing potential * all prognostic group exclusion criteria: * any of the following: * pregnant or lactating women. * presence of the following: 1. heart failure with lvef \<50% 2. liver enzymes, \>2 uln not attributed to hodgkin lymphoma. 3. another malignancy that is currently clinically significant or requires active intervention * early-stage disease (stage i- iia). * patients who are already participating to another clinical trial. * known history of hiv seropositive status * ecog performance status 3-4 * creatinin clearance \<50 ml/min * prior treatment for hodgkin lymphoma excluding steroids * medical or psychiatric conditions compromising the patient's ability to give informed consent * patients with serious active infection * pre-existing peripheral neuropathy (grade 2 or more).

Keywords: stage ii b classical hodgkin lymphoma stage iii classical hodgkin lymphoma stage iv classical hodgkin lymphoma
stereotactic radiosurgery in treating patients with spinal metastases

Conditions: Metastatic Cancer

Summary: rationale: stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. it may also help patients with spinal metastases live more comfortably. purpose: this phase i trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with spinal metastases.

objectives: * to implement cyberknife® technology for improving palliation in patients with spinal metastases. * to determine the maximum tolerated dose of cyberknife® hypofractionated stereotactic radiosurgery in these patients. * to evaluate functional and diffusion mri parameters in the spinal cord and tumor after treatment with cyberknife® radiosurgery. outline: patients undergo placement of gold fiducial markers at the time of open surgical resection or percutaneous needle biopsy. patients then undergo cyberknife® hypofractionated stereotactic radiosurgery over 30-90 minutes daily for 2-3 days. patients undergo functional mri and diffusion tensor imaging at baseline and then at 6 weeks and 6 months after completion of treatment. patients also complete a pain questionnaire at baseline and then at 3, 6, 9, 12, 18, and 24 months after completion of treatment. after completion of study treatment, patients are followed periodically for up to 2 years.

Eligibility criteria:
inclusion criteria: disease characteristics: * histologically confirmed metastatic spinal tumor * localized spinal metastasis, defined as one of the following: * solitary spinal metastasis * two contiguous spinal levels * no more than 2 adjacent spinal levels involved by a single tumor * involvement of ≤ 3 separate sites (e.g., c5, t5, and t12) * tumor size ≤ 5 cm patient characteristics: * karnofsky performance status 60-100% * life expectancy ≥ 6 months * negative pregnancy test * fertile patients must use effective contraception * must be ambulatory exclusion criteria: * not pregnant or nursing * no spinal instability * no rapid neurological decline * no bony retropulsions causing neurological abnormalities * no total paraplegia for \> 48 hours * no psychological issues that would preclude completion of study treatment prior concurrent therapy: * see disease characteristics * no prior treatment for spinal tumor that would result in potential overlap of radiotherapy fields * no treatment that is expected to exceed spinal cord tolerance or other regional normal tissue tolerance * no tumors that are exquisitely radiosensitive and controlled with conventional radiotherapy (e.g., lymphoma, leukemia, multiple myeloma, or germ cell tumors)

Keywords: spinal cord metastases
does emotional support decrease in vitro fertilization stress?

Conditions: In Vitro Fertilization; Psychological Stress

Summary: in vitro fertilization for infertility has been associated with a significant amount of treatment related stress for patients. in addition,stress levels increase between embryo transfer and pregnancy test, during this waiting period. the investigators evaluated whether or not brief interventions by phone by trained social workers influenced stress levels. our data showed that these interventions did not change levels, but confirmed that stress did increase during this time and that patients report wanting additional emotional support to improve stress during this period.


Eligibility criteria:
inclusion criteria: * all women (ages 18-45) undergoing their first fresh cycle of ivf using autologous oocytes where an embryo transfer occurred exclusion criteria: * \> 2nd cycle of ivf ivf using donor eggs or a gestational carrier * transfers with cryopreserved embryos * day 5 embryo transfers * self-reported history of depression or anxiety * already seeing a mental health professional * inability to speak or read english

Keywords: ivf stress infertility